Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab Based Therapy in HER2 Positive AGC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. pathology and medical imageology proven advanced gastric adenocarcinoma, inoperable;~2. received trastuzumab plus chemotherapy as the first-line palliative chemotherapy;~3. with measurable lesion with a diameter 20 mm using conventional computed tomography (CT) or magnetic resonance imaging (MRI) scans or 10 mm using spiral CT scans;~4. Eastern Cooperative Oncology Group performance status (ECOG PS ) of 0-2;~5. left ventricular ejection fraction(LVEF) more than 50 percents;~6. sufficient bone marrow, liver and renal function.~Exclusion Criteria:~1. received previous systemic therapy for advanced disease (except adjuvant/neoadjuvant chemotherapy completed at least 6 months before enrollment);~2. trastuzumab based adjuvant/neoadjuvant therapy;~3. treatment with any other anticancer therapy (lapatinib, immunotherapy, etc);~4. patients with heart failure, coronary artery disease or myocardial infarction within the previous 6 months.~5. trastuzumab based first line therapy started beyond 4 weeks from the first diagnoses of AGC.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HER2 positive AGC treated with H+CT (Type: None): HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).